Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2017

01-12-2017 | Colorectal Cancer

Reply: “Adjuvant” Hyperthermic Intraperitoneal Chemotherapy: A Call to Action

Author: David L. Morris, MD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2017

Login to get access

Excerpt

I read with interest the editorial of McAuliffe and Nash.1 We believe that neither this editorial nor the paper should be seen without context. The statement that “to date no study has definitely shown that hyperthermic intraperitoneal chemotherapy (HIPEC) in combination with cytoreductive surgery (CRS) is effective for peritoneal metastases of colorectal origin…” is one that we do not agree with. …
Literature
1.
McAuliffe JC, Nash GM. “Adjuvant” hyperthermic intraperitoneal chemotherapy: a call to action. Ann Surg Oncol. 2017;24:11–2.CrossRefPubMed
2.
Mirnezami R, Moran BJ, Harvey K, et al. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. World J Gastroenterol. 2014;20(38):14018–32.CrossRefPubMedPubMedCentral
3.
4.
Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental or standard of care? Ann Surg. 2008;248:829–35.PubMed
5.
Sammartino P, Sibio S, Biacchi D, et al. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Colorectal Dis. 2014;29(9):1081–9.CrossRefPubMed
6.
Elias D, Honore C, Dumont F, et al. Results of systematic second look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254(2)289–93.CrossRefPubMed
Metadata
Title
Reply: “Adjuvant” Hyperthermic Intraperitoneal Chemotherapy: A Call to Action
Author
David L. Morris, MD, PhD
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6171-1

Other articles of this Special Issue 3/2017

Annals of Surgical Oncology 3/2017 Go to the issue

Colorectal Cancer

Comment: Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer

Gynecologic Oncology

Comment on: Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study

Hepatobiliary Tumors

Yes-Associated Protein (YAP) is a Key Factor for Improving the Management of Cancer Treatments

Colorectal Cancer

Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older than 70 Years; Survival Benefit at Considerable Morbidity and Mortality: A Reply

Thoracic Oncology

Video-Assisted Thoracic Surgery for Patients with Advanced Stage Non-small Cell Lung Cancer

Head and Neck Oncology

Diffuse Microcalcifications of Only the Thyroid Gland Seen on Ultrasound: Clinical Implication and Diagnostic Approach